Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
News: Latest News
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors

ISA TanTec : to Acquire Auburn Leather Lace Business

03/01/2018 | 09:08am EDT

ISA TanTec is pleased to announce that it has signed definitive agreements to acquire the Auburn Leather brand, business and assets with closing in Q2 2018.

Key Auburn staff, including Lisa Howlett, will be retained to ensure continued high quality, character and consistency of the Auburn leather laces for which they are known throughout the industry. Auburn laces will be manufactured in ISA TanTec’s facilities using the same proprietary processes, hides, chemicals and equipment to ensure the authenticity and uniqueness of Auburn’s leather laces continues for our customers.

Auburn was established in 1863 and is the global leader in leather laces. Lisa Howlett, Auburn’s longstanding owner, will join the ISA team as the Auburn Brand Ambassador and will assist in taking the company to the next level by integrating Auburn into the ISA TanTec Group. The integration will create more value through an optimized supply chain as well as using a common sales and marketing structure on a global basis to better serve our clients.

ISA TanTec, the eco-friendly leather manufacturer, known for its LITE (Low Impact To the Environment) Trademark is majority owned by its founder, management, and Navis Capital partners, one of the largest private equity firms in Asia.


© Business Wire 2018
Latest news "Companies"
09:07aSHANGHAI ELECTRIC : Ranks 51st on ENR's 2021 Top 250 International Contractors List
AQ
09:07aDAIICHI SANKYO : ENHERTU® Reduced the Risk of Disease Progression or Death by 72% Versus Trastuzumab Emtansine (T-DM1) in Patients with HER2 Positive Metastatic Breast Cancer
BU
09:07aASTRAZENECA : ENHERTU® (fam-trastuzumab deruxtecan-nxki) reduced the risk of disease progression or death by 72% vs. trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer
BU
09:06aMERCK : KEYTRUDA® (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab Reduced Risk of Death by One-Third Versus Chemotherapy With or Without Bevacizumab as First-Line Treatment for Persistent, Recurrent or Metastatic Cervical Cancer
BU
09:06aMERCK : KEYTRUDA® (pembrolizumab) Demonstrated Superior Recurrence-Free Survival (RFS) in Patients With Resected High-Risk Stage II Melanoma Compared to Placebo in the Adjuvant Setting
BU
09:02aWINTRUST FINANCIAL : Follow These 5 Steps To Make Changing Banks Easier
PU
09:02aESMO CONGRESS 2021 : Efficacy and Safety of Poziotinib in Treatment-naïve NSCLC Harboring HER2 exon 20 Mutations: A Multinational Phase 2 Study (ZENITH20-4)
PU
09:00aUK business minister meets energy bosses over soaring gas prices
RE
08:46aSPECTRUM PHARMACEUTICALS : Presents Late Breaker Oral Presentation of Poziotinib Data in First-Line NSCLC Patients with HER2 Exon 20 Insertion Mutations at ESMO Congress 2021
BU
08:27aPRUDENTIAL : plans to raise $2.9 bln in Hong Kong share sale
RE
Latest news "Companies"